Mark Foletta

Mark G.
Foletta currently serves as Chairman at AMN Healthcare Services, Inc. since 2025, Lead Independent Director at DexCom, Inc. since 2015, Independent Director at Enanta Pharmaceuticals, Inc. since 2020, and is a Member of The Financial Executives Institute and Corporate Directors Forum.
Former positions include Independent Director at Anadys Pharmaceuticals, Inc. in 2011, Director at ViaCyte, Inc. from 2013 to 2022, Independent Director at Ambit Biosciences Corp.
in 2014, Independent Director at Regulus Therapeutics, Inc. from 2014 to 2018, Director at Islet Sciences, Inc. in 2013, Chief Financial Officer & Senior VP-Finance at Amylin Pharmaceuticals, Inc. from 2006 to 2012, Audit Manager at Ernst & Young LLP from 1986 to 2000, Chief Financial Officer at Biocept, Inc. from 2015 to 2016, Chief Financial Officer & Executive Vice President at Tocagen, Inc. from 2017 to 2020, Chief Financial Officer, Secretary & Senior VP at Intermark, Inc. from 1986 to 1997, Chief Financial Officer, Secretary & Senior VP at Triton Group Ltd. in 1997, and Principal at Triton Group Management, Inc. from 1997 to 2000.
Education includes undergraduate studies at the University of California, Santa Barbara.